KURA ONCOLOGY INC. - COMMON STOCK

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

11 3 2024 08:53:56 提供 NetDania Notify

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

07 3 2024 08:45:19 提供 NetDania Notify

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

06 3 2024 10:15:16 提供 NetDania Notify

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

06 3 2024 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

27 2 2024 15:01:00 提供 Nasdaq GlobeNewswire

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

26 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

22 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

20 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

30 1 2024 06:00:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces Oversubscribed $150 Million Private Placement

24 1 2024 06:00:57 提供 Nasdaq GlobeNewswire

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

08 12 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

28 11 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Reports Third Quarter 2023 Financial Results

02 11 2023 15:01:00 提供 Nasdaq GlobeNewswire

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

02 11 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

30 10 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology to Report Third Quarter 2023 Financial Results

26 10 2023 15:05:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

19 10 2023 06:30:00 提供 Nasdaq GlobeNewswire

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

17 10 2023 15:05:00 提供 Nasdaq GlobeNewswire